[go: up one dir, main page]

MXPA02012611A - Composicion anestesica, acuosa, clara. - Google Patents

Composicion anestesica, acuosa, clara.

Info

Publication number
MXPA02012611A
MXPA02012611A MXPA02012611A MXPA02012611A MXPA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A
Authority
MX
Mexico
Prior art keywords
clear aqueous
propofol
compositions
composition
bgr
Prior art date
Application number
MXPA02012611A
Other languages
English (en)
Inventor
Shilpa Kocharekar
Original Assignee
Bharat Serums Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums Vaccines Ltd filed Critical Bharat Serums Vaccines Ltd
Publication of MXPA02012611A publication Critical patent/MXPA02012611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se da a conocer un proceso para la preparacion de composiciones acuosas claras del propofol, adecuadas para la administracion parenteral. Estas composiciones consisten esencialmente de un complejo de inclusion del propofol con la 2-hidroxipropil-??-ciclodextrina. La formacion de complejo del propofol con la 2-hidroxipropil-??-ciclodextrina produce una composicion acuosa clara, la cual es estable en el autoclave y que sera efectiva como un agente anestesico.
MXPA02012611A 2000-06-21 2000-12-14 Composicion anestesica, acuosa, clara. MXPA02012611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (es) 2000-06-21 2000-06-21
PCT/IN2000/000124 WO2001097796A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Publications (1)

Publication Number Publication Date
MXPA02012611A true MXPA02012611A (es) 2004-07-30

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012611A MXPA02012611A (es) 2000-06-21 2000-12-14 Composicion anestesica, acuosa, clara.

Country Status (26)

Country Link
US (1) US7138387B2 (es)
EP (1) EP1299095B1 (es)
JP (1) JP4907833B2 (es)
KR (1) KR100810066B1 (es)
CN (1) CN1254237C (es)
AP (1) AP2002002674A0 (es)
AT (1) ATE267592T1 (es)
AU (2) AU2001235972B2 (es)
BG (1) BG107463A (es)
BR (1) BR0017268A (es)
CA (1) CA2414064C (es)
DE (1) DE60011149T2 (es)
DK (1) DK1299095T3 (es)
EA (1) EA005589B1 (es)
ES (1) ES2222271T3 (es)
HU (1) HUP0301646A3 (es)
IL (1) IL153387A0 (es)
IN (1) IN187686B (es)
MX (1) MXPA02012611A (es)
NO (1) NO20025999D0 (es)
NZ (1) NZ523643A (es)
PL (1) PL359624A1 (es)
PT (1) PT1299095E (es)
WO (1) WO2001097796A1 (es)
YU (1) YU2703A (es)
ZA (1) ZA200300336B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (es) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
KR20100112632A (ko) * 2001-12-28 2010-10-19 에이자이 아이엔씨. 수용성인 프로포폴 전구약물의 약제학적 수성 제제
EP1469886B8 (en) * 2002-02-01 2008-01-09 Shimoda Biotech (PTY) LTD Lyophilized pharmaceutical composition of propofol
WO2004010941A2 (en) 2002-07-29 2004-02-05 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
ES2685436T3 (es) * 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
JPWO2005067905A1 (ja) * 2004-01-14 2007-12-27 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
CA2580202A1 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
WO2007052295A2 (en) * 2005-08-12 2007-05-10 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
WO2009114580A2 (en) * 2008-03-11 2009-09-17 3M Innovative Properties Company Hardcoat composition
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
WO2011011167A2 (en) 2009-07-21 2011-01-27 3M Innovative Properties Company Curable composition, method of coating a phototool, and coated phototool
CN102686642B (zh) 2009-09-16 2016-06-29 3M创新有限公司 氟化涂料和用其制作的底片
WO2011034845A1 (en) 2009-09-16 2011-03-24 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
CA2852716C (en) 2011-11-29 2015-11-17 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
RU2667010C2 (ru) 2012-08-21 2018-09-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса
EP3407875A4 (en) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
IL153387A0 (en) 2003-07-06
HUP0301646A2 (hu) 2003-09-29
HUP0301646A3 (en) 2005-06-28
EP1299095A1 (en) 2003-04-09
YU2703A (sh) 2006-03-03
KR100810066B1 (ko) 2008-03-05
AU2001235972B2 (en) 2005-07-21
CA2414064C (en) 2013-01-08
DE60011149D1 (de) 2004-07-01
CA2414064A1 (en) 2001-12-27
CN1454085A (zh) 2003-11-05
EP1299095B1 (en) 2004-05-26
DK1299095T3 (da) 2004-10-11
CN1254237C (zh) 2006-05-03
ES2222271T3 (es) 2005-02-01
ATE267592T1 (de) 2004-06-15
NZ523643A (en) 2004-05-28
IN187686B (es) 2002-06-08
JP2003535893A (ja) 2003-12-02
DE60011149T2 (de) 2005-07-07
BG107463A (en) 2003-11-28
WO2001097796A1 (en) 2001-12-27
ZA200300336B (en) 2004-04-08
PT1299095E (pt) 2004-10-29
BR0017268A (pt) 2003-05-27
AP2002002674A0 (en) 2002-12-31
NO20025999L (no) 2002-12-13
EA200300047A1 (ru) 2003-06-26
AU3597201A (en) 2002-01-02
NO20025999D0 (no) 2002-12-13
US20040014718A1 (en) 2004-01-22
PL359624A1 (en) 2004-08-23
KR20030023875A (ko) 2003-03-20
JP4907833B2 (ja) 2012-04-04
US7138387B2 (en) 2006-11-21
EA005589B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
MXPA02012611A (es) Composicion anestesica, acuosa, clara.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
AR046651A1 (es) Composicion purgante colonica con agente aglutinante soluble
DK1157037T3 (da) GCSF-konjugater
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DE60133555D1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
PL1819227T3 (pl) Preparat farmaceutyczny decytabiny
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
HUP0303379A2 (hu) Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AR046464A1 (es) Multiparticulas de liberacion controlada con mejoradores de la disolucion

Legal Events

Date Code Title Description
FG Grant or registration